Arndts D, Leb G, Förster H J
Eur J Drug Metab Pharmacokinet. 1981;6(3):225-36. doi: 10.1007/BF03189492.
Radioactively labelled alinidine was administered intravenously (10 mg) and orally (40 mg) to 5 healthy volunteers and beagle dogs (3 animals for each administration route: 0.1 mg/kg body weight i.v. and 1 mg/kg body weight p.o.). Alinidine was totally absorbed in both species. Regardless of the route of administration man excreted the drug via the kidneys within 12 hours, almost entirely in the unchanged form. The blood plasma curves in man followed a multiexponential decline (t 1/2 alpha : 35 sec, t 1/2 beta : 44 min, t 1/2 gamma : 210 min). The maximum plasma levels of the drug were recorded in man, 45 min after oral administration. However, the rather slow decline of plasma radioactivity observed in dogs, corresponded well with the delayed urinary excretion of alinidine (50% of the administered dose) in this species. Dogs metabolized the drug extensively; seven different metabolites including the parent compound were isolated from canine urine. considerable interindividual differneces were found concerning the quantitive but not the qualitative metabolic pattern of alinidine in dogs. Structural analysis by mass spectrometry revealed oxidation, hydroxylation, and cleavage products of alinidine, altered in its imidazolin and/or allylic moiety. In both species no traces of clonidine were found, which was a predicted metabolite formed by the removal of the allylic sidechain of alinidine.
向5名健康志愿者和比格犬静脉注射(10毫克)和口服(40毫克)放射性标记的阿利尼定(每种给药途径3只动物:静脉注射0.1毫克/千克体重,口服1毫克/千克体重)。阿利尼定在两种物种中均被完全吸收。无论给药途径如何,人在12小时内通过肾脏排泄药物,几乎完全以未改变的形式排出。人的血浆曲线呈多指数下降(t 1/2α:35秒,t 1/2β:44分钟,t 1/2γ:210分钟)。口服给药后45分钟,人体记录到药物的最大血浆水平。然而,在狗身上观察到的血浆放射性下降相当缓慢,这与该物种中阿利尼定的延迟尿排泄(给药剂量的50%)相符。狗对药物进行了广泛的代谢;从犬尿中分离出包括母体化合物在内的七种不同代谢物。在狗身上,发现阿利尼定的定量代谢模式存在相当大的个体差异,但定性代谢模式没有差异。通过质谱进行的结构分析揭示了阿利尼定的氧化、羟基化和裂解产物,其咪唑啉和/或烯丙基部分发生了改变。在这两种物种中均未发现可乐定的痕迹,可乐定是通过去除阿利尼定的烯丙基侧链形成的预测代谢物。